World Health Organization Issues Alert Over Acute Shortage of Weight-Loss Injections
Less than 10% of people eligible to benefit from obesity jabs like Wegovy are able to get them, caution the global health agency as it publishes its initial guidance on the therapies.
Considering more than one billion people worldwide now obese, it is advocating for more widespread and fairer access to GLP-1 medication.
Per forecasts, over two billion are projected to be obese by 2030 without intervention.
"The new guidelines affirms that obesity is a chronic disease that can be managed with comprehensive and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are significant hurdles to broad availability to the injections that can aid individuals in losing substantial body mass, says the agency.
Skinny Jab Shortage
Despite the present most favorable outlook, the production of these medications might only reach approximately 100 million people – less than 10% of those who need them, as stated by the health organization.
The recommendation encourages nations and manufacturers to widen availability, through approaches like licensing agreements.
The intellectual property rights on a key compound – the primary ingredient of the drug Wegovy – is set to lapse in a number of nations in 2026.
The Way Weight-Loss Injections Operate
GLP-1 drugs replicate a body's own hormone to reduce digestion speed, curb appetite and enhance satiety so people consume fewer calories.
Individuals usually see weight reduction after several weeks of starting on the regular doses.
Studies suggests people may regain a significant portion a year later of discontinuing the treatment, when their typical hunger return.
To be above a healthy weight raises your likelihood for experiencing health problems, including diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight affects individuals in all nations and was responsible for millions of deaths worldwide in 2024, according to the health agency.